Randomized trials in PCNSL
| Induction . | Consolidation . |
|---|---|
| Completed trials | Completed trials |
| Medical Research Council | G-PCNSL-SG-1 – NCT00153530 |
| Phase 2, n = 53 (stopped early) | Phase 3, n = 551, ages ≥18 y |
| CHOP vs WBRT followed by CHOP33 | Arm 1: Methotrexate ± ifosfamide = > WBRT |
| IELSG 20—NCT00210314 | Arm 2: Methotrexate ± ifosfamide31 |
| Ongoing trials | |
| Phase 2; n = 79, ages 18-75 y | IESLG 32—NCT01011920 |
| Induction arm 1: Methotrexate + Cytarabine = > WBRT | Phase 2, n = 104, ages 18-70 y |
| Induction arm 2: Methotrexate = > WBRT18 | Consolidation arm 1: WBRT |
| ANOCEF-GOELAMS—NCT00503594 | Consolidation arm 1: HDT/ASCT |
| Phase 2, n = 95, ages ≥60 y | ANOCEF-GOELAMS—NCT00863460 |
| Arm 1: Methotrexate, procarbazine, vincristine, cytarabine | Phase 2, n = 100, ages 18-60 y |
| Arm 2: Methotrexate, temozolomide34 | (R-MBVP = > |
| IESLG 32—NCT01011920 | Consolidation arm 1: HDT/ASCT |
| Phase 2, n = 227, ages 18-70 y | Consolidation arm 2: WBRT |
| Induction arm 1: Methotrexate, cytarabine | RTOG 1114—NCT01399372 |
| Induction arm 2: Methotrexate, cytarabine, rituximab | Phase 2, n = 84, ages ≥18 y |
| Induction arm 3: Methotrexate, cytarabine, rituximab, thiotepa25 | Methotrexate, procarbazine, vincristine, rituximab = > |
| Ongoing trials | |
| ALLG/HOVON—EudraCT 2009-014722-42 | Consolidation arm 1: WBRT (lower dose) = > cytarabine |
| Phase 3, n = 200, ages 18-70 y | Consolidation arm 2: Cytarabine |
| Arm 1: Methotrexate, BCNU, teniposide, prednisone = > Cytarabine, WBRT | Alliance 51101—NCT01511562 |
| Arm 2: Methotrexate, BCNU, teniposide, prednisone = > Cytarabine, WBRT | Phase 2, n = 160, ages 18-75 y |
| Methotrexate, temozolomide, rituximab, cytarabine = > | |
| Consolidation arm 1: HDT/ASCT | |
| Consolidation arm 2: Etoposide, cytarabine | |
| MATRIX/IELSG43 | |
| Phase 2, n = 220, ages 18-70 y | |
| Methotrexate, cytarabine, thiotepa, rituximab (MATRix) = > | |
| Consolidation arm 1: HDT/ASCT | |
| Consolidation arm 2: Dexamethasone, ifosfamide, VP-16, carboplatin (DEViC) |
| Induction . | Consolidation . |
|---|---|
| Completed trials | Completed trials |
| Medical Research Council | G-PCNSL-SG-1 – NCT00153530 |
| Phase 2, n = 53 (stopped early) | Phase 3, n = 551, ages ≥18 y |
| CHOP vs WBRT followed by CHOP33 | Arm 1: Methotrexate ± ifosfamide = > WBRT |
| IELSG 20—NCT00210314 | Arm 2: Methotrexate ± ifosfamide31 |
| Ongoing trials | |
| Phase 2; n = 79, ages 18-75 y | IESLG 32—NCT01011920 |
| Induction arm 1: Methotrexate + Cytarabine = > WBRT | Phase 2, n = 104, ages 18-70 y |
| Induction arm 2: Methotrexate = > WBRT18 | Consolidation arm 1: WBRT |
| ANOCEF-GOELAMS—NCT00503594 | Consolidation arm 1: HDT/ASCT |
| Phase 2, n = 95, ages ≥60 y | ANOCEF-GOELAMS—NCT00863460 |
| Arm 1: Methotrexate, procarbazine, vincristine, cytarabine | Phase 2, n = 100, ages 18-60 y |
| Arm 2: Methotrexate, temozolomide34 | (R-MBVP = > |
| IESLG 32—NCT01011920 | Consolidation arm 1: HDT/ASCT |
| Phase 2, n = 227, ages 18-70 y | Consolidation arm 2: WBRT |
| Induction arm 1: Methotrexate, cytarabine | RTOG 1114—NCT01399372 |
| Induction arm 2: Methotrexate, cytarabine, rituximab | Phase 2, n = 84, ages ≥18 y |
| Induction arm 3: Methotrexate, cytarabine, rituximab, thiotepa25 | Methotrexate, procarbazine, vincristine, rituximab = > |
| Ongoing trials | |
| ALLG/HOVON—EudraCT 2009-014722-42 | Consolidation arm 1: WBRT (lower dose) = > cytarabine |
| Phase 3, n = 200, ages 18-70 y | Consolidation arm 2: Cytarabine |
| Arm 1: Methotrexate, BCNU, teniposide, prednisone = > Cytarabine, WBRT | Alliance 51101—NCT01511562 |
| Arm 2: Methotrexate, BCNU, teniposide, prednisone = > Cytarabine, WBRT | Phase 2, n = 160, ages 18-75 y |
| Methotrexate, temozolomide, rituximab, cytarabine = > | |
| Consolidation arm 1: HDT/ASCT | |
| Consolidation arm 2: Etoposide, cytarabine | |
| MATRIX/IELSG43 | |
| Phase 2, n = 220, ages 18-70 y | |
| Methotrexate, cytarabine, thiotepa, rituximab (MATRix) = > | |
| Consolidation arm 1: HDT/ASCT | |
| Consolidation arm 2: Dexamethasone, ifosfamide, VP-16, carboplatin (DEViC) |
ALLG, Australasian Leukaemia and Lymphoma Group; ANOCEF, Association des Neuro-Oncologue d’Expression Française; GOELAMS, Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang; G-PCNSL-SG, German Primary CNS Lymphoma Study Group; HDT/ASCT, high-dose chemotherapy and autologous stem cell transplantation; HOVON, Stichting Hemato-Oncologie voor Volwassenen Nederland (Dutch-Belgian Cooperative Trial Group for Hematology Oncology); IELSG, International Extranodal Lymphoma Study Group; NCT, national clinical trial; RTOG, Radiation Therapy Oncology Group; WBRT, whole-brain radiation therapy.